GeneDx Reports Second Quarter 2026 Financial Results
GeneDx reported Q2 revenue of $114.4 million, up 11% year-over-year, driven by a 32% increase in exome and genome testing volume. The company returned to adjusted profitability with $0.4 million in adjusted net income and reaffirmed its full-year 2026 revenue guidance of $475 to $490 million.
Key figures
- Eps
- 0.01
- Revenue
- 114400000
- Guidance
- FY26 revenue $475M-$490M; Q3 revenue $122M-$124M
- Revenue Yoy
- 11%
- Term loan increase
- 50000000
- Exome genome revenue
- 100300000
- Cash position pro forma
- 188000000
- Exome genome volume yoy
- 32%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.